As research progresses and standard reference ranges are defined, we can expect serum-based neurodegenerative biomarkers (like NfL, GFAP) to become part of routine MS care for tracking disease progression and treatment effectiveness, while CSF-based measures are more efficient for certain diagnostic or research applications where maximum specificity is required [5]. This evidence concerns the gene NEFL and myeloid sarcoma.